Cabezas M C, de Bruin T W, Jansen H, Kock L A, Kortlandt W, Erkelens D W
Department of Internal Medicine, University Hospital, Utrecht, The Netherlands.
Arterioscler Thromb. 1993 Jun;13(6):804-14. doi: 10.1161/01.atv.13.6.804.
Postprandial chylomicron remnant clearance was studied in six patients with familial combined hyperlipidemia (FCH) and seven control subjects by using an oral retinyl palmitate (RP) fat-loading test. The chylomicron remnant clearance (Sf < 1,000 fraction), expressed as the area under the RP curve (AUC-RP), was delayed in FCH subjects (65.05 +/- 12.84 hours x [mg/L]) compared with control subjects (25.1 +/- 5.4 hours x [mg/L]; p = 0.01). Postprandial lipoprotein particle size and composition in the Sf > 1,000 fraction were different between FCH and control subjects as analyzed by molecular-sieve chromatography. Fasting high density lipoprotein cholesterol was lower in FCH patients (0.54 +/- 0.09 mmol/L) than in control subjects (0.89 +/- 0.05 mmol/L; p < 0.01). Mean plasma postheparin lipoprotein lipase and hepatic lipase activities were similar between FCH patients (94 +/- 25 and 427 +/- 57 milliunits/mL, respectively) and control subjects (126 +/- 16 and 362 +/- 33 milliunits/mL, respectively). In FCH, a 54% reduction (p < 0.05) of plasma triglycerides to 2.63 +/- 0.41 mmol/L by drug treatment resulted in an enhanced, but not normalized, clearance of chylomicron remnants (39.4 +/- 6.0 hours x [mg/L]). Univariate regression analysis revealed that in FCH subjects the changes in fasting plasma apolipoprotein C-III concentrations after therapy were significantly associated with the changes in chylomicron remnant AUC-RP (r = 0.87; p = 0.02). Delayed elimination of atherogenic chylomicron remnants may contribute to the increased risk of premature atherosclerosis in FCH.
通过口服视黄醇棕榈酸酯(RP)脂肪负荷试验,对6例家族性混合型高脂血症(FCH)患者和7例对照者的餐后乳糜微粒残粒清除情况进行了研究。以RP曲线下面积(AUC-RP)表示的乳糜微粒残粒清除率(Sf<1000组分),FCH患者(65.05±12.84小时×[mg/L])较对照者(25.1±5.4小时×[mg/L];p=0.01)延迟。通过分子筛色谱分析,FCH患者和对照者Sf>1000组分中的餐后脂蛋白颗粒大小和组成不同。FCH患者空腹高密度脂蛋白胆固醇(0.54±0.09 mmol/L)低于对照者(0.89±0.05 mmol/L;p<0.01)。FCH患者(分别为94±25和427±57毫单位/mL)和对照者(分别为126±16和362±33毫单位/mL)的平均血浆肝素后脂蛋白脂肪酶和肝脂肪酶活性相似。在FCH中,药物治疗使血浆甘油三酯降低54%(p<0.05)至2.63±0.41 mmol/L,导致乳糜微粒残粒清除率增强但未恢复正常(39.4±6.0小时×[mg/L]))。单变量回归分析显示,在FCH患者中,治疗后空腹血浆载脂蛋白C-III浓度的变化与乳糜微粒残粒AUC-RP的变化显著相关(r=0.87;p=0.02)。致动脉粥样硬化乳糜微粒残粒的清除延迟可能导致FCH患者过早发生动脉粥样硬化的风险增加。